BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Core Insights - BioAtla, Inc. reported its financial results for the full year and fourth quarter ended December 31, 2025, highlighting a focus on advancing its clinical programs while exploring strategic options to maximize shareholder value [1][3]. Corporate Updates - The company initiated a formal process to explore strategic options, including the potential sale of assets and partnerships, engaging Tungsten Advisors as its exclusive financial advisor [3]. - A reduction in force and cost-containment measures were implemented to align resources with near-term priorities, affecting the timing and scope of clinical development programs [4]. - The ongoing Phase 1 study of BA3182 in adenocarcinomas remains a priority, with the company committed to its clinical development despite potential delays [4]. Financial Results - Research and development (R&D) expenses for Q4 2025 were $8.0 million, down from $11.7 million in Q4 2024. For the full year, R&D expenses totaled $43.6 million, compared to $63.1 million in 2024, primarily due to lower program development costs and reduced headcount-related expenses [5]. - Collaboration and other revenue for Q4 2025 was $2.0 million, reflecting a milestone payment from Context Therapeutics, compared to $11.0 million for the full year 2024 [6]. - General and administrative (G&A) expenses decreased to $3.3 million in Q4 2025 from $4.6 million in Q4 2024, with full-year G&A expenses at $17.7 million compared to $21.8 million in 2024 [7]. - The net loss for Q4 2025 was $9.8 million, an improvement from a net loss of $14.9 million in Q4 2024. The full-year net loss was $59.6 million, down from $69.8 million in 2024 [8]. Cash Position - As of December 31, 2025, cash and cash equivalents were $7.1 million, a significant decrease from $49.0 million at the end of 2024 [10][23]. - The company expects to extend its runway through cost reductions and the utilization of a Standby Equity Purchase Agreement while pursuing strategic options [10]. Clinical Pipeline - BioAtla is advancing several clinical assets, including BA3182, a bispecific T-cell engager antibody for advanced adenocarcinoma, and Ozuriftamab Vedotin (Oz-V), targeting oropharyngeal squamous cell carcinoma [13][15]. - Oz-V has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck, with a potential market opportunity exceeding $7 billion [15]. Patent Portfolio - BioAtla holds extensive patent coverage for its CAB platform technology, with over 780 active patent matters, including more than 500 issued patents, covering various methods and compositions related to its product candidates [11].